Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy

Chitturi, Kalyan R.; Burns, Ethan; Muhsen, Ibrahim N.; Anand, Kartik; Trachtenberg, Barry

doi:10.1007/s11912-022-01215-1

Cited by 12 publications

(2 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before initiating treatment with EGFR-TKIs, a rigorous baseline risk assessment must be performed on all patients, and baseline cardiovascular risk factors, including obesity, diabetes, hypertension, smoking, etc., must be carefully considered. Cardiac assessment at baseline level, regular dynamic monitoring in treatment with EGFR-TKIs, and post-treatment follow-up, including blood pressure measurement and electrocardiogram, cardiac imaging, and dynamic monitoring of biomarkers, should be routinely performed to determine whether patients would benefit from treatment with EGFR-TKIs and to adjust treatment prior to irreversible cardiac injury ( 44 ).…”

Section: Evaluation and Monitoring Of Egfr-tkis-induced Cardiotoxicitymentioning

confidence: 99%

EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring

Wang,

Qiu,

Deng

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

The advent of targeted drug therapy has greatly changed the treatment landscape of advanced non-small cell lung cancer(NSCLC), but the cardioxic side effects of targeted drug anti-cancer therapy seriously affect the prognosis of NSCLC, and it has become the second leading cause of death in cancer patients. Therefore, early identification of the cardiotoxic side effects of targeted drugs is crucial for the prevention and treatment of cardiovascular diseases. The cardiotoxic side effects that may be caused by novel targeted drugs epidermal growth factor receptor inhibitors, including thromboembolic events, heart failure, cardiomyopathy, arrhythmia and hypertension, are discussed, and the mechanisms of their respective adverse cardiovascular reactions are summarized, to provide useful recommendations for cardiac management of patients with advanced lung cancer to maximize treatment outcomes for lung cancer survivors. Clinicians need to balance the risk-benefit ratio between targeted therapy for malignant tumors and drug-induced cardiotoxicity, and evaluate and monitor TKIs-induced cardiotoxicity through electrocardiogram, cardiac imaging, biomarkers, etc., so as to remove the susceptibility risk factors as soon as possible and provide a reference for the clinical use of such drugs in the treatment of malignant tumors.

show abstract

Section: Evaluation and Monitoring Of Egfr-tkis-induced Cardiotoxicitymentioning

confidence: 99%

EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring

Wang,

Qiu,

Deng

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…TKIs targeting the erbB receptor family also include lapatinib (erbB1/2), neratinib (erbB1/2/4), afatinib (erbB), and dacomitinib (erbB1/2/4). They have been reported to induce cardiotoxicity at a relatively low overall level [179][180][181][182].…”

Section: Immunotherapymentioning

confidence: 99%

Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology

Liang

2022

IJMS

View full text Add to dashboard Cite

Chemotherapy, radiotherapy, targeted therapy, and immunotherapy have brought hope to cancer patients. With the prolongation of survival of cancer patients and increased clinical experience, cancer-therapy-induced cardiovascular toxicity has attracted attention. The adverse effects of cancer therapy that can lead to life-threatening or induce long-term morbidity require rational approaches to prevention and treatment, which requires deeper understanding of the molecular biology underpinning the disease. In addition to the drugs used widely for cardio-protection, traditional Chinese medicine (TCM) formulations are also efficacious and can be expected to achieve “personalized treatment” from multiple perspectives. Moreover, the increased prevalence of cancer in patients with cardiovascular disease has spurred the development of “reverse cardio-oncology”, which underscores the urgency of collaboration between cardiologists and oncologists. This review summarizes the mechanisms by which cancer therapy induces cardiovascular toxicity, the combination of antineoplastic and cardioprotective drugs, and recent advances in reverse cardio-oncology.

show abstract